References
- Juweid M E, Cheson B D. Role of positron emission tomography in lymphoma. J Clin Oncol 2007; 23: 4577–4580
- Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
- Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
- Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fuorine-18 fluorodeoxyglucose positron emission tomography. J Clin Oncol 2007; 23: 4652–4661
- Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J A, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876
- Valencak J, Becherer A, Der-Petrossian M, Trautinger F, Raderer M, Hoffmann M. Positron emission tomography with [18F] 2-fluoro-d-2-deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica 2004; 89: 115–116
- Kumar R, Xiu Y, Zhuang H M, Alavi A. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol 2006; 155: 357–363
- Tsai E Y, Taur A, Espinosa L, Quon A, Johnson D, Dick S, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006; 142: 577–584
- Wohrer S, Chott A, Drach J, Puspok A, Hejna M, Hoffmann M, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol 2004; 15: 1680–1683
- Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003; 52: 347–351
- Hadithi M, Mallant M, Oudejans J, van Waesberghe J H, Mulder C J, Comans E F. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006; 47: 1622–1627
- Bishu S, Quigley J M, Schmitz J, Bishu S R, Stemm R A, Olsasky S M, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007; 48: 1531–1538
- Kako S, Izutsu K, Ohta Y, Minatani Y, Makoto S, Momose T, et al. FDG-PET in T-cell and NK-cell neoplasm. Ann Oncol, in press
- Shoder H, Noy A, Gonen M, Weng L, Green D, Erdi Y E, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 2643–2651
- Sugawara Y, Zasadny K R, Kison P V, Baker L H, Wahl R L. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy. PET imaging results. J Nucl Med 1999; 40: 1456–1462